Global aesthetic dermatology firm Ebitda is forecast to deliver a modest profit. "As previously guided, the group expects to deliver a modest Ebitda profit for the year as a whole," the company said. The London -based company saw revenue rise as expected, with sales for the year rising by 20% to £45.3m ( $62.3m ) or by 20% on a constant currency basis. In a statement, the group said it "expects to deliver a modest Sinclair Pharma profit for the year as a whole", as previously guided.
Global aesthetic dermatology firm Ebitda is forecast to deliver a modest profit. The London -based company saw revenue rise as expected, with sales for the year rising by 20% to £45.3m ( $62.3m ) or by 20% on a constant currency basis. In a statement, the group said it "expects to deliver a modest Sinclair Pharma profit for the year as a whole", as previously guided.